A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases

Objectives Informing an international task force updating the consensus statement on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) selectively targeting interleukin-6 (IL-6) pathway in the context of immune-mediated inflammatory diseases.Methods A systematic liter...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Désirée van der Heijde, Maxime Dougados, Naveed Sattar, Tsutomu Takeuchi, Iain B McInnes, Daniel Aletaha, Tanja A Stamm, Christian Dejaco, Josef S Smolen, Gerd R Burmester, Kevin Winthrop, Michael Trauner, Angelo Ravelli, Andreas Kerschbaumer, Eva Chwala, Kastriot Kastrati, Marieke J H Voshaar
Format:	Artykuł
Język:	English
Wydane:	BMJ Publishing Group 2022-09-01
Seria:	RMD Open
Dostęp online:	https://rmdopen.bmj.com/content/8/2/e002359.full

Podobne zapisy

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
od: Antonio Gasbarrini, i wsp.
Wydane: (2020-02-01)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
od: Juthamas Prawjaeng, i wsp.
Wydane: (2023-05-01)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
od: M. J. H. Voshaar, i wsp.
Wydane: (2022-01-01)

The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination
od: Selma Tobudic, i wsp.
Wydane: (2023-02-01)

Predictors of response to bDMARDs and tsDMARDs in psoriatic arthritis: a pilot study on the role of musculoskeletal ultrasound
od: Giacomo Cozzi, i wsp.
Wydane: (2024-12-01)

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
od: Marie Kostine, i wsp.
Wydane: (2022-10-01)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
od: Humby, F, i wsp.
Wydane: (2019)

A SURVEY OF DMARD PREFERENCES OF UK RHEUMATOLOGISTS
od: Douglas, K, i wsp.
Wydane: (2003)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
od: Mysler E, i wsp.
Wydane: (2021-06-01)

The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study
od: Jie Chang, i wsp.
Wydane: (2024-01-01)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
od: Coates, L, i wsp.
Wydane: (2017)

Percentage of progressors in imaging: can we ignore regressors?
od: Sofia Ramiro, i wsp.
Wydane: (2019-05-01)

Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone
od: Edwards, C, i wsp.
Wydane: (2008)

DMOADs and DMARDs in the treatment of patients with joint and spine diseases
od: O. A. Shavlovskaya
Wydane: (2024-02-01)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
od: Michael D George, i wsp.
Wydane: (2021-04-01)

DMARDs–Gut Microbiota Feedback: Implications in the Response to Therapy
od: Oscar Zaragoza-García, i wsp.
Wydane: (2020-10-01)

Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone
od: Carl K Edwards, i wsp.
Wydane: (2012-12-01)

Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis
od: Coates, LC, i wsp.
Wydane: (2016)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
od: Seogsong Jeong, i wsp.
Wydane: (2022-07-01)

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
od: Thomas Wilke, i wsp.
Wydane: (2017-08-01)

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
od: Fleischmann, R, i wsp.
Wydane: (2023)

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.
od: Jobanputra, P, i wsp.
Wydane: (2004)

Combination therapy with DMARDs and biological agents in collagen-induced arthritis.
od: Williams, R, i wsp.
Wydane: (1999)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
od: Kai Wei, i wsp.
Wydane: (2022-03-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
od: Basant Kumar Maheshwari
Wydane: (2018-01-01)

Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment
od: Caporali, R, i wsp.
Wydane: (2022)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
od: Gerd Burmester, i wsp.
Wydane: (2020-02-01)

Anti-Müllerian Hormone Serum Levels as Biomarker of Ovarian Reserve in Adult Women with Juvenile Idiopathic Arthritis Treated with csDMARDs and/or bDMARDs: A Pilot Study
od: Clara Di Mario, i wsp.
Wydane: (2024-10-01)

Burden and determinants of multi-b/tsDMARD failure in psoriatic arthritis
od: Rebecca H. Haberman, i wsp.
Wydane: (2025-03-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
od: Maria Sergeevna Voronina, i wsp.
Wydane: (2012-10-01)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
od: Marco Infante, i wsp.
Wydane: (2022-04-01)

Efficacy of JAK Inhibitors versus DMARDs in the Treatment of Polymyalgia Rheumatica in China
od: Gu J, i wsp.
Wydane: (2023-07-01)

Rheumatoid arthritis seems to have DMARD treatment decision influenced by fibromyalgia
od: Rafael Mendonça da Silva Chakr, i wsp.

Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study
od: Juan M. Reyes, i wsp.
Wydane: (2023-03-01)

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
od: Tanja Alexandra Stamm, i wsp.
Wydane: (2018-08-01)

P160 Drug survival in SLE: real world data from the vienna lupus cohort
od: Daniel Aletaha, i wsp.
Wydane: (2024-03-01)

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
od: Van De Laar CJ, i wsp.
Wydane: (2020-04-01)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study
od: Ritchlin, CT, i wsp.
Wydane: (2023)

Harnessing the small intestinal axis to resolve systemic inflammation
od: Mark Bodmer, i wsp.
Wydane: (2022-11-01)

JAK inhibitors and infections risk: focus on herpes zoster
od: Flavia Sunzini, i wsp.
Wydane: (2020-06-01)